AusperBio reports AHB-137 sustained functional cure in 16 of 17 evaluable NA-treated hepatitis B patients at 12 months off ...

Researchers found 44 cancer-targeting T cell receptors in routine clinical genomics data from 150,000 tumours. Read how this ...

Brii Bio's Phase IIb ENRICH data show BRII-179 priming drove 42% HBsAg loss in hepatitis B. Read the full results and what ...

Anaheim Bio launches with an oversubscribed €40M Series A to advance ANA-1, a CPPD inhibitor, toward the clinic. Learn how ...

Johnson & Johnson's Rybrevant Faspro earns FDA accelerated approval for recurrent or metastatic HNSCC. Learn who qualifies ...

Alfasigma's Jyseleca (filgotinib) is now EU-approved for adults with active axial spondyloarthritis. Read what it means for ...

Alamar Biosciences (Nasdaq: ALMR) and Finland-based Nightingale Health have launched UKB-PRISM, a study of 80,000 UK Biobank ...

Roche is using Chai Discovery's AI models across multiple drug discovery programs. Read the full story on this latest 2026 ...

Novo Nordisk is terminating its cardiometabolic RNA-editing deal with Korro Bio, effective February 2027. Read what it means for Korro's programs and rights.

Moderna's mRNA-2808 yields four confirmed responses in Phase I/II myeloma study targeting BCMA, GPRC5D and FcRH5. Read the ...

Cambridge spinout T-Therapeutics closes $133m Series B to advance TCR bispecifics in cancer and autoimmune disease. Read the ...

Acepodia dosed the first patient in a Phase I trial of ACE723, a GPC3-targeted dual-payload ADC for liver cancer. Read the ...